Kojin Therapeutics
Vision
Kojin’s mission is to transform the future of medicine by harnessing groundbreaking discoveries in cell state and ferroptosis biology to create novel therapies and cures for diseases traditionally considered intractable.
Approach
Kojin Therapeutics is the first biopharmaceutical company using a proprietary approach to cell state and ferroptosis biology to develop novel therapeutics for diseases of high unmet need. The company is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables development of selective therapies for a broad range of intractable diseases. By utilizing a novel non-genetic classification of cell states instead of conventional cell types, Kojin’s platform identifies specific targets for therapeutic intervention to develop medicines tailored to each disease that selectively target affected tissues.
Kojin Therapeutics is addressing
CEO:
Luba Greenwood
Founders:
Stuart Schreiber
Benjamin Cravatt
Stephanie Dougan
Vasanthi Viswanathan
First investment:
January 2020